Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lesko

Showing results (171-180 of 231) with videos related to

Pageof 24
Sort By:
Journal of Clinical Pharmacology|July 30, 2021
Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective ConcentrationsAhmed Elmokadem, Christopher D Bruno, Conrad Housand, et al.
Clinical Pharmacology and Therapeutics|August 3, 1999
In vitro metabolic interaction studies: experience of the Food and Drug AdministrationR Yuan, T Parmelee, J D Balian, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 3, 2024
Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulationMarian Klose, Rodrigo Cristofoletti, Carolina de Miranda Silva, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 20, 2015
Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS)Xiaoyan Zhang, Issam S Hamadeh, Shuang Song, et al.
The American Journal of Cardiology|April 1, 1988
Relation between serum nifedipine concentration and hemodynamic effects in nonobstructive hypertrophic cardiomyopathyS Betocchi, R O Bonow, R O Cannon, et al.
Clinical Pharmacology and Therapeutics|March 9, 2012
Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitorMd L T Vieira, P Zhao, E G Berglund, et al.
Clinical Pharmacology and Therapeutics|June 15, 2001
Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference reportG R Galluppi, M C Rogge, L K Roskos, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 21, 2007
Qualification of biomarkers for drug development in organ transplantationGilbert J Burckart, Shashi Amur, Federico M Goodsaid, et al.
Journal of Pharmaceutical Sciences|October 1, 1986
Pharmacokinetics of intravenous bepridil in patients with coronary diseaseL J Lesko, J R Benotti, J S Alpert, et al.
Clinical Pharmacology and Therapeutics|November 5, 1999
Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modelingG J Singh, W P Adams, L J Lesko, et al.
Pageof 24

Showing results (171-180 of 231) with videos related to

Sort By:
Pageof 24
Journal of Clinical Pharmacology|July 30, 2021
Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective ConcentrationsAhmed Elmokadem, Christopher D Bruno, Conrad Housand, et al.
Clinical Pharmacology and Therapeutics|August 3, 1999
In vitro metabolic interaction studies: experience of the Food and Drug AdministrationR Yuan, T Parmelee, J D Balian, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 3, 2024
Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulationMarian Klose, Rodrigo Cristofoletti, Carolina de Miranda Silva, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 20, 2015
Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS)Xiaoyan Zhang, Issam S Hamadeh, Shuang Song, et al.
The American Journal of Cardiology|April 1, 1988
Relation between serum nifedipine concentration and hemodynamic effects in nonobstructive hypertrophic cardiomyopathyS Betocchi, R O Bonow, R O Cannon, et al.
Clinical Pharmacology and Therapeutics|March 9, 2012
Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitorMd L T Vieira, P Zhao, E G Berglund, et al.
Clinical Pharmacology and Therapeutics|June 15, 2001
Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference reportG R Galluppi, M C Rogge, L K Roskos, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 21, 2007
Qualification of biomarkers for drug development in organ transplantationGilbert J Burckart, Shashi Amur, Federico M Goodsaid, et al.
Journal of Pharmaceutical Sciences|October 1, 1986
Pharmacokinetics of intravenous bepridil in patients with coronary diseaseL J Lesko, J R Benotti, J S Alpert, et al.
Clinical Pharmacology and Therapeutics|November 5, 1999
Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modelingG J Singh, W P Adams, L J Lesko, et al.
Pageof 24